We are live on
!
Find out more
AA
AlphaCentric Advisors Portfolio holdings
AUM
$100M
This Fund
S&P 500
This Quarter
Est. Return
+9.61%
1 Year Est. Return
–
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$149M
AUM Growth
-$27.3M
(-16%)
Cap. Flow
-$34.7M
Cap. Flow
% of AUM
-23.28%
Top 10 Holdings %
Top 10 Hldgs %
25.17%
Holding
298
New
63
Increased
40
Reduced
80
Closed
82
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
ABVX
Abivax
ABVX
|
+$2.73M |
| 2 |
Pfizer
PFE
|
+$2.42M |
| 3 |
argenx
ARGX
|
+$2.33M |
| 4 |
VYNE Therapeutics
VYNE
|
+$2.08M |
| 5 |
Invesco NASDAQ 100 ETF
QQQM
|
+$1.95M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Neurocrine Biosciences
NBIX
|
+$3.38M |
| 2 |
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
|
+$2.95M |
| 3 |
iShares 1-3 Year Treasury Bond ETF
SHY
|
+$2.75M |
| 4 |
TSVT
2seventy bio
TSVT
|
+$2.58M |
| 5 |
Crinetics Pharmaceuticals
CRNX
|
+$2.44M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 59.47% |
| 2 | Real Estate | 11.94% |
| 3 | Financials | 4.93% |
| 4 | Consumer Discretionary | 2.41% |
| 5 | Industrials | 2.3% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
101
Copart
CPRT
$25.6B
| $212K | 0.14% |
+4,318
| New | +$204K |
|
102
Boston Scientific
BSX
$65.4B
| $211K | 0.14% |
3,653
-540
| -13% | -$28.8K |
|
103
Republic Services
RSG
$68.4B
| $209K | 0.14% |
+1,265
| New | +$196K |
|
104
Visa
V
$682B
| $208K | 0.14% |
+800
| New | +$197K |
|
105
Roper Technologies
ROP
$36.6B
| $208K | 0.14% |
+381
| New | +$196K |
|
106
CME Group
CME
$88.5B
| $204K | 0.14% |
+967
| New | +$206K |
|
107
McDonald's
MCD
$190B
| $200K | 0.13% |
674
-95
| -12% | -$25.9K |
|
108
O'Reilly Automotive
ORLY
$71.3B
| $194K | 0.13% |
3,060
-465
| -13% | -$29.4K |
|
109
Vanguard Real Estate ETF
VNQ
$39.6B
| $194K | 0.13% |
+2,193
| New | +$174K |
|
110
Arthur J. Gallagher & Co
AJG
$65.2B
| $191K | 0.13% |
+849
| New | +$201K |
|
111
Royal Caribbean
RCL
$77B
| $191K | 0.13% |
1,474
+530
| +56% | +$54K |
|
112
Monster Beverage
MNST
$95.4B
| $190K | 0.13% |
3,295
-488
| -13% | -$26.1K |
|
113
Lamb Weston
LW
$6.46B
| $189K | 0.13% |
1,745
-252
| -13% | -$24.3K |
|
114
Vanguard Global ex-US Real Estate ETF
VNQI
$3.49B
| $187K | 0.13% |
+4,382
| New | +$175K |
|
115
JPMorgan Chase
JPM
$907B
| $186K | 0.13% |
+1,096
| New | +$166K |
|
116
Carnival Corporation Ltd
CCL
$36.2B
| $186K | 0.13% |
10,054
+3,457
| +52% | +$50.2K |
|
117
Uber
UBER
$147B
| $185K | 0.12% |
3,008
-299
| -9% | -$15.6K |
|
118
Mondelez International
MDLZ
$78.3B
| $184K | 0.12% |
2,542
-358
| -12% | -$24.5K |
|
119
iShares US & Intl High Yield Corp Bond ETF
GHYG
$185M
| $176K | 0.12% |
3,976
-594
| -13% | -$25.1K |
|
120
State Street SPDR Bloomberg High Yield Bond ETF
JNK
$7.36B
| $174K | 0.12% |
1,842
-261
| -12% | -$23.8K |
|
121
iShares Fallen Angels USD Bond ETF
FALN
$1.64B
| $174K | 0.12% |
6,607
-1,030
| -13% | -$26K |
|
122
FlexShares High Yield Value-Scored Bond Index Fund
HYGV
$1.1B
| $174K | 0.12% |
4,253
-547
| -11% | -$21.7K |
|
123
iShares 0-5 Year High Yield Corporate Bond ETF
SHYG
$7.61B
| $173K | 0.12% |
4,090
-584
| -12% | -$24.1K |
|
124
Norwegian Cruise Line
NCLH
$8.93B
| $166K | 0.11% |
8,299
+3,248
| +64% | +$52.1K |
|
125
J.M. Smucker
SJM
$12B
| $164K | 0.11% |
1,298
-178
| -12% | -$20.6K |
|
Similar funds
WCM
FCM
BIA
AGAM
E
HCM
AC
OIS
AlphaCentric Advisors's Q4 2023 Portfolio in Review
As of Q4 2023, AlphaCentric Advisors held 298 positions worth $149M, down 16% from $176M the previous quarter. Its ten largest holdings account for 25% of the portfolio.
AlphaCentric Advisors withdrew a net $34.7M in Q4 2023, closing 82 positions and reducing 80 holdings. Its most notable exit was Neurocrine Biosciences, an estimated $3.38M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 59% of assets, down from 62% a quarter earlier, followed by Real Estate and Financials.
Against the trend, AlphaCentric Advisors opened a new position in Abivax worth $2.86M.
- AlphaCentric Advisors's largest Q4 2023 buy was Abivax: 267,500 shares worth $2.86M.
- AlphaCentric Advisors added most to argenx in Q4 2023, an estimated $2.33M increase.
- AlphaCentric Advisors's biggest Q4 2023 reduction was iShares 1-3 Year Treasury Bond ETF, cutting an estimated $2.75M.
- AlphaCentric Advisors fully exited Neurocrine Biosciences in Q4 2023, selling an estimated $3.38M.
- AlphaCentric Advisors's ten largest holdings make up 25% of its $149M portfolio in Q4 2023.
- AlphaCentric Advisors opened 63 new positions and closed 82 in Q4 2023.
- AlphaCentric Advisors's portfolio value fell 16% quarter-over-quarter to $149M.
Based on AlphaCentric Advisors's 13F filing for Q4 2023, filed 14 Feb 2024.